CA2323536C - Formulation pharmaceutique comportant un 2-[[(2-pyridinyl)methyl]sulfinyl]benzimidazole dote d'une activite anti-ulcereuse et procede de preparation de cette formulation - Google Patents

Formulation pharmaceutique comportant un 2-[[(2-pyridinyl)methyl]sulfinyl]benzimidazole dote d'une activite anti-ulcereuse et procede de preparation de cette formulation Download PDF

Info

Publication number
CA2323536C
CA2323536C CA002323536A CA2323536A CA2323536C CA 2323536 C CA2323536 C CA 2323536C CA 002323536 A CA002323536 A CA 002323536A CA 2323536 A CA2323536 A CA 2323536A CA 2323536 C CA2323536 C CA 2323536C
Authority
CA
Canada
Prior art keywords
formulation according
benzimidazole
formulation
coating
coating layer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CA002323536A
Other languages
English (en)
Other versions
CA2323536A1 (fr
Inventor
Kristian Lund Henriksen
Helle Kann
Karen Eichstedt Sorensen
Soren Bols Pedersen
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sandoz AS
Original Assignee
GEA Farmaceutisk Fabrik AS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=8093069&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CA2323536(C) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by GEA Farmaceutisk Fabrik AS filed Critical GEA Farmaceutisk Fabrik AS
Publication of CA2323536A1 publication Critical patent/CA2323536A1/fr
Application granted granted Critical
Publication of CA2323536C publication Critical patent/CA2323536C/fr
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
    • A61K9/5078—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings with drug-free core
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5026—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin
    • A61K9/5042—Cellulose; Cellulose derivatives, e.g. phthalate or acetate succinate esters of hydroxypropyl methylcellulose

Landscapes

  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

L'invention se rapporte à une formulation pharmaceutique orale comportant des granules constitués d'un noyau inerte recouvert d'une couche comportant un 2-[[(2-pyridinyl)méthyl]sulfinyl]benzimidazole doté d'une activité anti-ulcéreuse, un désintégrant et un tensioactif dans une matrice d'une substance d'enrobage à l'état fondu constituée essentiellement d'un ou de plusieurs esters de glycérol et d'acides gras, une couche de séparation et une couche de revêtement gastro-résistant. L'invention se rapporte également à un procédé de préparation de ladite formulation mettant en oeuvre une technique d'enrobage avec un produit fondu pour la préparation de la couche contenant le benzimidazole.
CA002323536A 1998-03-20 1999-03-17 Formulation pharmaceutique comportant un 2-[[(2-pyridinyl)methyl]sulfinyl]benzimidazole dote d'une activite anti-ulcereuse et procede de preparation de cette formulation Expired - Fee Related CA2323536C (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DK199800397A DK173431B1 (da) 1998-03-20 1998-03-20 Farmaceutisk formulering omfattende en 2-[[(2-pyridinyl)methyl]sulfinyl]benzimidazol med anti-ulcusaktivitet samt fremgangs
DK0397/98 1998-03-20
PCT/DK1999/000137 WO1999048498A1 (fr) 1998-03-20 1999-03-17 Formulation pharmaceutique comportant un 2- [[(2- pyridinyl) methyl] sulfinyl] benzimidazole dote d'une activite anti-ulcereuse et procede de preparation de cette formulation

Publications (2)

Publication Number Publication Date
CA2323536A1 CA2323536A1 (fr) 1999-09-30
CA2323536C true CA2323536C (fr) 2009-05-19

Family

ID=8093069

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002323536A Expired - Fee Related CA2323536C (fr) 1998-03-20 1999-03-17 Formulation pharmaceutique comportant un 2-[[(2-pyridinyl)methyl]sulfinyl]benzimidazole dote d'une activite anti-ulcereuse et procede de preparation de cette formulation

Country Status (20)

Country Link
US (1) US6391342B1 (fr)
EP (1) EP1061920B1 (fr)
AR (1) AR014753A1 (fr)
AT (1) ATE218863T1 (fr)
AU (1) AU744596B2 (fr)
CA (1) CA2323536C (fr)
CZ (1) CZ291943B6 (fr)
DE (1) DE69901804T2 (fr)
DK (2) DK173431B1 (fr)
EA (1) EA002502B1 (fr)
ES (1) ES2177246T3 (fr)
HU (1) HU226580B1 (fr)
IS (1) IS2265B (fr)
NO (1) NO20004667L (fr)
NZ (1) NZ507115A (fr)
PL (1) PL192437B1 (fr)
TR (1) TR200002696T2 (fr)
TW (1) TW529951B (fr)
WO (1) WO1999048498A1 (fr)
ZA (1) ZA200004757B (fr)

Families Citing this family (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100627614B1 (ko) * 1998-04-20 2006-09-25 에자이 가부시키가이샤 안정화된 벤즈이미다졸계 화합물 함유 조성물로 이루어지는 의약제제
ZA9810765B (en) * 1998-05-28 1999-08-06 Ranbaxy Lab Ltd Stable oral pharmaceutical composition containing a substituted pyridylsulfinyl benzimidazole.
US6248363B1 (en) * 1999-11-23 2001-06-19 Lipocine, Inc. Solid carriers for improved delivery of active ingredients in pharmaceutical compositions
CZ20014405A3 (cs) 1999-06-07 2002-04-17 Byk Gulden Lomberg Chemische Fabrik Gmbh Léková forma
EP1064938A1 (fr) * 1999-06-28 2001-01-03 Sanofi-Synthelabo Formes pharmaceutiques à libération contrôlée avec au moins une impulsion temporelle
ES2168043B1 (es) 1999-09-13 2003-04-01 Esteve Labor Dr Forma farmaceutica solida oral de liberacion modificada que contiene un compuesto de bencimidazol labil en medio acido.
AR021347A1 (es) 1999-10-20 2002-07-17 Cipla Ltd Una composicion farmaceutica que contiene acido(s) bisfosfoncio o sal(es) del mismo y un proceso de preparacion de la misma
WO2001032185A1 (fr) * 1999-11-02 2001-05-10 Cipla Ltd. Composition pharmaceutique renfermant au moins un acide bisphosphonique ou un de ses sels et son procede de preparation
US20060034937A1 (en) * 1999-11-23 2006-02-16 Mahesh Patel Solid carriers for improved delivery of active ingredients in pharmaceutical compositions
US20030180352A1 (en) * 1999-11-23 2003-09-25 Patel Mahesh V. Solid carriers for improved delivery of active ingredients in pharmaceutical compositions
DE19959419A1 (de) * 1999-12-09 2001-06-21 Ratiopharm Gmbh Stabile galenische Zubereitungen umfassend ein Benzimidazol und Verfahren zu ihrer Herstellung
ES2191521B1 (es) * 2000-11-22 2005-02-16 Laboratorios Belmac, S.A. Nueva formulacion galenica del omeprazol en forma de comprimidos, procedimiento para su preparacion y aplicaciones en medicina humana y en veterinaria.
MY148805A (en) * 2002-10-16 2013-05-31 Takeda Pharmaceutical Controlled release preparation
WO2004089333A2 (fr) * 2003-02-28 2004-10-21 Cadila Healthcare Limited Formulation de benzimidazole stable
ES2234393B2 (es) * 2003-04-29 2006-09-01 Laboratorios Belmac, S.A. "formulaciones de pelets de compuestos bencimidazolicos antiulcerosos y labiles al acido".
TWI372066B (en) * 2003-10-01 2012-09-11 Wyeth Corp Pantoprazole multiparticulate formulations
BRPI0415242B8 (pt) * 2003-10-10 2021-05-25 Ethypharm Sa microgrânulos de liberação gradual contendo extrato de gingko biloba e o processo para fabricar estes
JP2007517038A (ja) * 2003-12-30 2007-06-28 ドクター レディズ ラボラトリーズ リミテッド 薬学的組成物
US20050181052A1 (en) * 2004-02-17 2005-08-18 Patel Satishkumar A. Lansoprazole microtablets
US20050214371A1 (en) * 2004-03-03 2005-09-29 Simona Di Capua Stable pharmaceutical composition comprising an acid labile drug
PL1746980T3 (pl) 2004-05-07 2012-03-30 Nycomed Gmbh Farmaceutyczna postać dawkowania zawierająca peletki i sposób jej wytwarzania
CA2570916C (fr) * 2004-06-16 2013-06-11 Tap Pharmaceutical Products, Inc. Forme posologique d'ipp a doses multiples
US20080050444A1 (en) * 2005-12-16 2008-02-28 Rajneesh Taneja Pharmaceutical compositions of ilaparazole
WO2007100984A2 (fr) * 2006-02-24 2007-09-07 Allergan, Inc. Formes de dosage
EP2026768B1 (fr) * 2006-06-01 2018-02-28 Dexcel Pharma Technologies Ltd. Formulation pharmaceutique comprenant des unités multiples
US8486452B2 (en) * 2007-07-20 2013-07-16 Mylan Pharmaceuticals Inc. Stabilized tolterodine tartrate formulations
US8110226B2 (en) * 2007-07-20 2012-02-07 Mylan Pharmaceuticals Inc. Drug formulations having inert sealed cores
US11304960B2 (en) 2009-01-08 2022-04-19 Chandrashekar Giliyar Steroidal compositions
US20100239681A1 (en) * 2009-03-20 2010-09-23 Biokey, Inc. Controlled Release Particulates Containing Water-Insoluble Drug
WO2010122583A2 (fr) 2009-04-24 2010-10-28 Rubicon Research Private Limited Compositions pharmaceutiques orales comprenant des substances labiles en milieu acide
EP2319504A1 (fr) * 2009-11-07 2011-05-11 Laboratorios Del. Dr. Esteve, S.A. Forme pharmaceutique solide
US9034858B2 (en) 2010-11-30 2015-05-19 Lipocine Inc. High-strength testosterone undecanoate compositions
US20180153904A1 (en) 2010-11-30 2018-06-07 Lipocine Inc. High-strength testosterone undecanoate compositions
US9358241B2 (en) 2010-11-30 2016-06-07 Lipocine Inc. High-strength testosterone undecanoate compositions
US20120148675A1 (en) 2010-12-10 2012-06-14 Basawaraj Chickmath Testosterone undecanoate compositions
CN103202820B (zh) * 2012-01-11 2016-03-30 浙江亚太药业股份有限公司 一种稳定的兰索拉唑肠溶胶囊及其制备方法
WO2016033556A1 (fr) 2014-08-28 2016-03-03 Lipocine Inc. Esters de (17-β)-hydroxy-4-androstène-3-one biodisponibles à l'état solide
US20170246187A1 (en) 2014-08-28 2017-08-31 Lipocine Inc. (17-ß)-3-OXOANDROST-4-EN-17-YL TRIDECANOATE COMPOSITIONS AND METHODS OF THEIR PREPARATION AND USE
WO2016174664A1 (fr) 2015-04-29 2016-11-03 Dexcel Pharma Technologies Ltd. Compositions à désintégration par voie orale
US20160361322A1 (en) 2015-06-15 2016-12-15 Lipocine Inc. Composition and method for oral delivery of androgen prodrugs
WO2017145146A1 (fr) 2016-02-25 2017-08-31 Dexcel Pharma Technologies Ltd. Compositions comprenant des inhibiteurs de la pompe à protons
US10076494B2 (en) 2016-06-16 2018-09-18 Dexcel Pharma Technologies Ltd. Stable orally disintegrating pharmaceutical compositions
US20180147215A1 (en) 2016-11-28 2018-05-31 Lipocine Inc. Oral testosterone undecanoate therapy
TWI795381B (zh) 2016-12-21 2023-03-11 比利時商健生藥品公司 作為ｍａｌｔ１抑制劑之吡唑衍生物
JP2021531348A (ja) 2018-07-20 2021-11-18 リポシン，インク． 肝臓病
US12404260B2 (en) 2019-04-11 2025-09-02 Janssen Pharmaceutica Nv Pyridine rings containing derivatives as MALT1 inhibitors

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE8301182D0 (sv) 1983-03-04 1983-03-04 Haessle Ab Novel compounds
CA1327010C (fr) 1986-02-13 1994-02-15 Tadashi Makino Compositions pharmaceutiques contenant un compose anti-ulcereux de type benzimidazole et sa production
GB2189698A (en) 1986-04-30 1987-11-04 Haessle Ab Coated omeprazole tablets
GB2189699A (en) 1986-04-30 1987-11-04 Haessle Ab Coated acid-labile medicaments
US5026560A (en) 1987-01-29 1991-06-25 Takeda Chemical Industries, Ltd. Spherical granules having core and their production
ES2024993A6 (es) 1990-12-31 1992-03-01 Genesis Para La Investigacion Procedimiento de obtencion de un preparado farmaceutico oral conteniendo omeprazol.
TW209174B (fr) 1991-04-19 1993-07-11 Takeda Pharm Industry Co Ltd
YU48263B (sh) 1991-06-17 1997-09-30 Byk Gulden Lomberg Chemische Fabrik Gmbh. Postupak za dobijanje farmaceutskog preparata na bazi pantoprazola
DK0519144T3 (da) * 1991-06-21 1998-03-23 Ilsan Ilac Ve Hammaddeleri San Ny galenisk proces for omeprazol indeholdende pellets
SE9200858L (sv) 1992-03-20 1993-09-21 Kabi Pharmacia Ab Metod för framställning av pellets med fördröjd frisättning
FR2692146B1 (fr) 1992-06-16 1995-06-02 Ethypharm Sa Compositions stables de microgranules d'omeprazole gastro-protégés et leur procédé d'obtention.
AU4513393A (en) 1992-07-17 1994-02-14 Astra Aktiebolag Pharmaceutical composition containing antiulcer agent
ES2087823B1 (es) 1994-07-13 1997-02-16 Estudes Et Richerches Pharma E Formulacion de microgranulos gastroresistentes de omeprazol y su procedimiento de fabricacion.
ES2094694B1 (es) 1995-02-01 1997-12-16 Esteve Quimica Sa Nueva formulacion farmaceuticamente estable de un compuesto de bencimidazol y su proceso de obtencion.
SE9500478D0 (sv) 1995-02-09 1995-02-09 Astra Ab New pharmaceutical formulation and process
US5708017A (en) * 1995-04-04 1998-01-13 Merck & Co., Inc. Stable, ready-to-use pharmaceutical paste composition containing proton pump inhibitors
CH687810A5 (de) 1995-05-24 1997-02-28 Mepha Ag Pelletformulierung mit Omeprazol.
JP3198337B2 (ja) * 1995-09-21 2001-08-13 ファーマ パス エルエルシー 酸不安定性ベンゾイミダゾールを含有する新規組成物及びその製造方法
SE9600072D0 (sv) * 1996-01-08 1996-01-08 Astra Ab New oral formulation of two active ingredients II
PT101826A (pt) 1996-02-06 1997-09-30 Medinfar Produtos Farmaceutico Processo para a preparacao de microgranulos contendo omeprazole
EP0968204A1 (fr) 1997-03-07 2000-01-05 A/S GEA Farmaceutisk Fabrik Procede de preparation de 2- 2-pyridinyl)methyl]sulfynyl]-1h-benzimidazoles et nouveaux composes a utiliser dans ledit procede

Also Published As

Publication number Publication date
NZ507115A (en) 2002-09-27
CZ291943B6 (cs) 2003-06-18
DK39798A (da) 1999-09-21
ES2177246T3 (es) 2002-12-01
HU226580B1 (en) 2009-04-28
DK1061920T3 (da) 2002-07-15
CZ20003458A3 (cs) 2001-03-14
NO20004667L (no) 2000-11-09
ATE218863T1 (de) 2002-06-15
AR014753A1 (es) 2001-03-28
DK173431B1 (da) 2000-10-23
AU2714899A (en) 1999-10-18
PL342840A1 (en) 2001-07-16
IS5628A (is) 2000-09-13
EP1061920B1 (fr) 2002-06-12
DE69901804T2 (de) 2002-12-12
EP1061920A1 (fr) 2000-12-27
DE69901804D1 (de) 2002-07-18
US6391342B1 (en) 2002-05-21
TW529951B (en) 2003-05-01
IS2265B (is) 2007-07-15
HUP0101178A2 (hu) 2001-08-28
EA200000970A1 (ru) 2001-02-26
NO20004667D0 (no) 2000-09-19
TR200002696T2 (tr) 2000-12-21
EA002502B1 (ru) 2002-06-27
CA2323536A1 (fr) 1999-09-30
WO1999048498A1 (fr) 1999-09-30
PL192437B1 (pl) 2006-10-31
AU744596B2 (en) 2002-02-28
ZA200004757B (en) 2001-05-30

Similar Documents

Publication Publication Date Title
CA2323536C (fr) Formulation pharmaceutique comportant un 2-[[(2-pyridinyl)methyl]sulfinyl]benzimidazole dote d'une activite anti-ulcereuse et procede de preparation de cette formulation
EP1371361B1 (fr) Nouvelle forme de suppositoire renfermant un composé actif acidolabile
RU2214232C2 (ru) Пероральная фармацевтическая лекарственная форма с продолжительным высвобождением
EP1108425B1 (fr) Nouvelles préparations pharmaceutiques multi-unitaires stables contenant des benzimidazoles substitués
AU751609B2 (en) Oral pharmaceutical preparation comprising an antiulcer activity compound, and process for its production
US6551621B1 (en) Gastroprotected omeprazole microgranules, method for obtaining same and pharmaceutical preparations
US20040213847A1 (en) Delayed release pharmaceutical compositions containing proton pump inhibitors
SK286625B6 (sk) Farmaceutický prípravok na báze omeprazolu
WO2011140446A2 (fr) Formulations pharmaceutiques
NZ289958A (en) Oral enteric coated medicament containing a magnesium salt of omeprazole having a degree of crystallinity which is higher than 70%, used to inhibit gastric acid secretion
US20240033224A1 (en) Enteric-coated pellet, method for preparing same and formulation comprising same
WO2005077342A1 (fr) Microcomprimes de lansoprazole gastroresistants
JPH0320215A (ja) 有核顆粒製剤およびその製造法
EP2345408A2 (fr) Formulations de médicament labiles acides
WO2005034924A1 (fr) Pastilles a enrobage enterique comprenant de l'esomeprazole, capsule de gelatine dure renfermant celles-ci et procede de preparation associe
WO2004098573A1 (fr) Composition pharmaceutique amelioree et stable contenant des benzimidazoles substitues et son procede de preparation
EP1594479A1 (fr) Compositions orales stables de benzimidazole et leurs procedes de preparation
US20030228363A1 (en) Stabilized pharmaceutical compositons containing benzimidazole compounds
WO2003103638A1 (fr) Compositions pharmaceutiques stabilisees contenant des composes de benzimidazole
EP3380084B1 (fr) Formulations d'oméprazole
CA2547398A1 (fr) Compositions stables de benzimidazole a administration orale et leurs procedes de preparation
RU2821366C1 (ru) Пеллеты с энтеросолюбильным покрытием, способ их получения и содержащие их составы
AU695723C (en) New oral pharmaceutical formulation containing magnesium salt of omeprazole
WO2006111853A2 (fr) Formes posologiques solides stables d'un medicament labile en milieu acide
KR100983655B1 (ko) 벤즈이미다졸 유도체의 경구용 제제

Legal Events

Date Code Title Description
EEER Examination request
MKLA Lapsed